Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MMSE Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Tau Networks in Psychotic Alzheimer's Disease

NCT05847192
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
Interventions
[18F]-PI2620 PET scan
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
65 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 27, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 27, 2026, 11:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

NCT04951284
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 27, 2026, 11:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Feasibility and Validity of A Novel Computer Based Battery of Assessments in the Elderly

NCT02109419
View directory record Official record
Conditions
Computerized Assessment Feasibility and Validity
Interventions
HHT-G, HHT-D, Geriatric Depression Scale (DGS), MMSE
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
60 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 27, 2026, 11:29 AM EDT
Completed No phase listed Observational

PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION

NCT03999879
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Measure of OxPhos upregulation, lactate (measured with 1H-MRSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
70 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

NCT02553603
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 27, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional Results available

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

NCT02663271
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
Interventions
Bevacizumab, Optune, Brain MRI, Quality of Life Questionnaires
Drug · Device · Other
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Functional Prehabilitation and Major Elective Surgery

NCT01943773
View directory record Official record
Conditions
Surgical Complication, Physical Therapy, Timed Up and Go
Interventions
Functional Assessment, Prehabilitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Physiological Investigations of Movement Disorders

NCT01019343
View directory record Official record
Conditions
Parkinson's Disease, Tourette's Syndrome, Tic Disorders, Dystonia, Movement Disorders
Interventions
Transcranial Direct Current Stimulation (tDCS), Eye-tracking Device, Pulsed vibrator, Gait Trainer Treadmill (GTT), Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA, iMobility, QMAT, Treadmill Test, Arm Intellistretch Device, Transcranial Sonography (TCS), Behavioral tasks, TMS single/paired pulse, MEG, EEG, MRI techniques, Peripheral Nerve Stimulation, EMG, Trancutaneous spinal direct current stimulation (tsDCS)
Procedure · Device · Other + 1 more
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease

NCT00305903
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine, memantine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 27, 2026, 11:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

NCT00908999
View directory record Official record
Conditions
Anosognosia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

NCT02759887
View directory record Official record
Conditions
Down Syndrome, Alzheimer's Dementia
Interventions
biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
Procedure · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Disclosing Dementia Risk Based on Plasma Phosphorylated Tau

NCT05377060
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Plasma p-tau risk disclosure, Standard risk disclosure
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

NCT03467152
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Irsenontrine, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Sun City, Arizona • Anaheim, California • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Not applicable Interventional

ToolBox Detect: Low Cost Detection of Cognitive Decline in Primary Care Settings

NCT04852601
View directory record Official record
Conditions
Cognitive Dysfunction, Dementia
Interventions
ToolboxDetect
Other
Lead sponsor
Northwestern University
Other
Eligibility
65 Years and older
Enrollment
35,403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 27, 2026, 11:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

NCT02266563
View directory record Official record
Conditions
Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
Interventions
Amyvid PET Scan, T807 PET scan
Drug
Lead sponsor
Samuel Gandy
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 27, 2026, 11:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Event-Related Potential (ERP) Components in Clinical Diagnosis

NCT05673759
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
Interventions
Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
Device · Behavioral
Lead sponsor
Boston University
Other
Eligibility
20 Years to 90 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

NCT02947893
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth
Drug
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 27, 2026, 11:29 AM EDT
Completed Phase 2 Interventional

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

NCT00397696
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] 5-IA
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 27, 2026, 11:29 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

NCT04228666
View directory record Official record
Conditions
Alzheimer Disease
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 27, 2026, 11:29 AM EDT
Completed No phase listed Observational

Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia

NCT01695551
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Data Collection Forms
Other
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 27, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional Results available

Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases

NCT00814463
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
MMSE, QOL via FACT-Br, MRI, Post-operative SRS
Behavioral · Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 27, 2026, 11:29 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 27, 2026, 11:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients

NCT04950673
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome, COVID Long-Haul
Interventions
Cognivue
Device
Lead sponsor
Cognivue, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Irvine, California • Visalia, California • Boca Raton, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 27, 2026, 11:29 AM EDT